Isabel Virella‐Lowell

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients

Isabel Virella‐Lowell, A Poirier, Kye Chesnut et al. · Gene Therapy · 2000 · 92 citations

Life Sciences, Infectious Diseases, Molecular Biology +16

Enhancing rAAV vector expression in the lung

Isabel Virella‐Lowell, Benjamin D. Zusman, Kevin D. Foust et al. · The Journal of Gene Medicine · 2005 · 62 citations

Life Sciences, Genetics, Molecular Biology +17

Defective Acid Sphingomyelinase Pathway with <i>Pseudomonas aeruginosa</i> Infection in Cystic Fibrosis

Hong Yu, Youssef H. Zeidan, Bill X. Wu et al. · American Journal of Respiratory Cell and Molecular Biology · 2009 · 52 citations · Full text

Life Sciences, Immunology, Microbiology +17

Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell Line

Isabel Virella‐Lowell, John-David Herlihy, Barry Liu et al. · Molecular Therapy · 2004 · 46 citations · Full text

Life Sciences, Molecular Biology, Pathobiology +17